Organigram Global (OGI) to Release Quarterly Earnings on Tuesday

Organigram Global (NASDAQ:OGI) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, August 11th. Analysts expect Organigram Global to announce earnings of ($0.01) per share and revenue of $68.1960 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

Organigram Global (NASDAQ:OGI) last posted its earnings results on Tuesday, May 12th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $42.99 million during the quarter, compared to analyst estimates of $50.56 million. Organigram Global had a negative net margin of 9.22% and a negative return on equity of 13.41%. On average, analysts expect Organigram Global to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organigram Global Stock Performance

Shares of NASDAQ OGI traded up $0.00 during trading hours on Tuesday, hitting $0.97. The company’s stock had a trading volume of 295,995 shares, compared to its average volume of 655,557. Organigram Global has a 12 month low of $0.85 and a 12 month high of $2.24. The stock has a market cap of $136.47 million, a price-to-earnings ratio of -7.51 and a beta of 1.46. The business has a 50-day simple moving average of $1.00 and a 200-day simple moving average of $1.26.

Hedge Funds Weigh In On Organigram Global

A number of institutional investors have recently bought and sold shares of OGI. Millennium Management LLC purchased a new stake in shares of Organigram Global in the 4th quarter worth about $1,260,000. Two Sigma Investments LP purchased a new position in Organigram Global during the 3rd quarter valued at about $907,000. Renaissance Technologies LLC lifted its position in Organigram Global by 43.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,405,348 shares of the company’s stock valued at $2,361,000 after acquiring an additional 423,900 shares during the period. Goldman Sachs Group Inc. lifted its position in Organigram Global by 82.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 466,585 shares of the company’s stock valued at $784,000 after acquiring an additional 210,391 shares during the period. Finally, Lazard Asset Management LLC bought a new stake in Organigram Global during the fourth quarter worth about $280,000. 34.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on OGI. Weiss Ratings reiterated a “sell (d)” rating on shares of Organigram Global in a report on Tuesday, June 9th. Wall Street Zen downgraded Organigram Global from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Organigram Global presently has a consensus rating of “Hold”.

Organigram Global Company Profile

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.